BioCentury
ARTICLE | Clinical News

Briviact regulatory update

February 3, 2017 12:40 AM UTC

FDA accepted for review an sNDA from UCB for Briviact brivaracetam as monotherapy to treat partial-onset seizures in epileptics ages ≥16. Last year, the agency approved the high affinity synaptic vesi...

BCIQ Company Profiles

UCB S.A.